On Thursday 14 March 2024, the Oncology Drug Advisory Committee (ODAC) will discuss new drug application (NDA) 217779 for Imetelstat for injection, submitted by Geron Corporation for the proposed indication for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents.